Completed OBSERVATIONAL NCT00626769

Third Year Evaluation on Genistein Efficacy and Safety

Safety Profile and Bone Efficacy of the Phytoestrogen Genistein in a Cohort of Osteopenic, Postmenopausal Women After Three Years of Treatment: a Follow-up Study

Sponsor: Primus Pharmaceuticals

Conditions Menopause Osteopenia

Interventions aglycone genistein placebo

Updated 10 times since 2017 Last updated: May 18, 2009 Started: Jul 31, 2005 Primary completion: Jul 31, 2006 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Menopause and Osteopenia and is currently completed. Primus Pharmaceuticals leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: PHASE2_PHASE3 → None
Aug 2017 — Apr 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Aug 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Primus Pharmaceuticals
University of Messina

Data source: University of Messina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.